[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.87. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
April 19, 2000

Hypertension Trial Surprise

Author Affiliations
 

Not Available

Not Available

JAMA. 2000;283(15):1950. doi:10.1001/jama.283.15.1950-JHA00002-2-1

The National Heart, Lung, and Blood Institute (NHLBI) has prematurely halted one arm of a major trial of hypertension drugs because patients taking one of the drugs—an α-adrenergic blocker—did not fare as well as patients taking a more traditional diuretic.

The main portion of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was designed to compare four classes of drugs: an α-adrenergic blocker (doxazosin), a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and a diuretic (chlorthalidone).

First Page Preview View Large
First page PDF preview
First page PDF preview
×